NCT06400264 2024-05-06
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)
National Cancer Institute (NCI)
Phase 2 Withdrawn
Clinical Trials
9 trialsNCT04439305 2020-07-20
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT01571726 2019-12-16
Imaging Studies and the Development of Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT01660997 2019-12-16
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT01647165 2019-12-12
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT03856112 2019-03-26
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT01479582 2018-12-21
Providing Access to Cord Blood Units for Transplants
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT01251172 2017-09-28
RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00112879 2013-07-10
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Withdrawn